Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study.
De With RR, Rienstra M, Smit MD, Weijs B, Zwartkruis VW, Hobbelt AH, Alings M, Tijssen JGP, Brügemann J, Geelhoed B, Hillege HL, Tukkie R, Hemels ME, Tieleman RG, Ranchor AV, Van Veldhuisen DJ, Crijns HJGM, Van Gelder IC.
De With RR, et al. Among authors: zwartkruis vw.
Europace. 2019 Apr 1;21(4):563-571. doi: 10.1093/europace/euy311.
Europace. 2019.
PMID: 30629160
Clinical Trial.